BioSpace21h
Neurocrine Gains ‘High-Risk/High-Reward’ Depression Asset From Takeda
Little information has emerged about osavampator, a potentially first-in-class drug, since its promising Phase II performance last spring.
FiercePharma23h
Fierce Pharma Asia—Takeda's next CEO; Enhertu's novel FDA nod; East Asian American C-suite execs
Takeda is promoting U.S. chief Julie Kim to be its next CEO. AstraZeneca and Daiichi's Enhertu has won an FDA nod to expand into HER2-ultralow breast cancer. | Takeda is promoting U.S. chief Julie Kim ...